David Mcclung Biography and Net Worth

CFO of BioCardia

Mr. David McClung has served as our Chief Financial Officer since September 2017 and has been with the Company since September 2013, also serving as Vice President of Finance from March 2016 to August 2017 and as Senior Director of Finance & Controller from September 2013 to February 2016. Mr. McClung has finance and accounting experience in publicly and privately financed organizations, including startup enterprises, large public companies and middle-market businesses. Before joining our company, Mr. McClung served as Director of Finance and Controller at Sonitus Medical, Inc., a privately-held manufacturer of an FDA cleared prosthetic hearing device for the treatment of single-sided deafness and conductive hearing loss. Prior to that, Mr. McClung served as Controller at NextWave Pharmaceuticals, Inc. a specialty pharmaceutical company acquired by Pfizer, Inc. Mr. McClung spent his early career in public accounting and finance functions at other companies, including Matson Navigation, Inc., The Clorox Company and KPMG LLP. Mr. McClung earned a Bachelor of Arts degree in Accounting from Georgia State University, graduating with honors. He is an actively licensed CPA and member of the AICPA and the California Society of CPAs.

What is David Mcclung's net worth?: The estimated net worth of David Mcclung is at least $49.87 thousand as of June 30th, 2025. Mcclung owns 47,950 shares of BioCardia stock worth more than $49,868 as of October 2nd. This net worth evaluation does not reflect any other assets that Mcclung may own. Learn More about David Mcclung's net worth.
How do I contact David Mcclung?: The corporate mailing address for Mcclung and other BioCardia executives is 320 Soquel Way, Sunnyvale, CA, 94085. BioCardia can also be reached via phone at (650) 226-0123 and via email at [email protected]. Learn More on David Mcclung's contact information.
Has David Mcclung been buying or selling shares of BioCardia?: David Mcclung has not been actively trading shares of BioCardia over the course of the past ninety days. Most recently, on Monday, June 30th, David Mcclung bought 4,819 shares of BioCardia stock. The stock was acquired at an average cost of $2.08 per share, with a total value of $10,023.52. Following the completion of the transaction, the chief financial officer now directly owns 47,950 shares of the company's stock, valued at $99,736. Learn More on David Mcclung's trading history.
Who are BioCardia's active insiders?: BioCardia's insider roster includes Peter Altman (CEO), and David Mcclung (CFO). Learn More on BioCardia's active insiders.
Are insiders buying or selling shares of BioCardia?: In the last twelve months, BioCardia insiders bought shares 26 times. They purchased a total of 169,900 shares worth more than $162,947.00. The most recent insider tranaction occured on September, 29th when CEO Peter Altman bought 1,000 shares worth more than $1,030.00. Insiders at BioCardia own 17.4% of the company. Learn More about insider trades at BioCardia.
Information on this page was last updated on 9/29/2026.

David Mcclung Insider Trading History at BioCardia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/30/2025	Buy	4,819	$2.08	$10,023.52	47,950
10/10/2022	Buy	133	$31.05	$4,129.65	5,234
11/5/2018	Buy	106	$38.40	$4,070.40
10/12/2018	Buy	33	$39.60	$1,306.80
9/25/2018	Buy	190	$36.75	$6,982.50
3/21/2018	Buy	50	$28.50	$1,425.00

David Mcclung Buying and Selling Activity at BioCardia

BioCardia Company Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Today's Range

Now: $1.04

$1.03

$1.05

50 Day Range

MA: $1.02

$0.77

$1.25

2 Week Range

Now: $1.04

$0.75

$1.80

Volume

48,337 shs

Average Volume

1,130,786 shs

Market Capitalization

$15.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62